| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
30,185 |
23,697 |
$2.17M |
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
30,592 |
22,460 |
$1.42M |
| 99204 |
Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity |
10,431 |
8,312 |
$1.16M |
| 99203 |
Office or other outpatient visit for the evaluation and management of a new patient, low complexity |
13,545 |
10,178 |
$932K |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
21,828 |
14,447 |
$633K |
| 99051 |
|
24,585 |
20,202 |
$122K |
| 87811 |
Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19) |
3,519 |
3,022 |
$94K |
| 87804 |
Infectious agent antigen detection by immunoassay; Influenza, each type |
7,519 |
3,398 |
$65K |
| 87880 |
Infectious agent antigen detection by immunoassay; Streptococcus, group A |
6,622 |
5,405 |
$53K |
| 99212 |
Office or other outpatient visit for the evaluation and management of an established patient, straightforward |
789 |
610 |
$23K |
| 99202 |
Office or other outpatient visit for the evaluation and management of a new patient, straightforward |
182 |
157 |
$10K |
| 99384 |
|
35 |
28 |
$4K |
| 81025 |
|
751 |
662 |
$3K |
| 99383 |
|
48 |
30 |
$3K |
| 36415 |
Collection of venous blood by venipuncture |
1,382 |
1,155 |
$3K |
| 71046 |
Radiologic examination, chest; 2 views |
247 |
200 |
$3K |
| 99215 |
Prolong outpt/office vis |
16 |
13 |
$2K |
| 99385 |
|
12 |
12 |
$1K |
| 87426 |
Infectious agent antigen detection, SARS-CoV-2 (COVID-19) |
55 |
50 |
$1K |
| 94640 |
Pressurized or nonpressurized inhalation treatment for acute airway obstruction |
210 |
189 |
$1K |
| 99173 |
|
219 |
181 |
$1K |
| 92552 |
|
134 |
108 |
$1K |
| 93000 |
|
107 |
89 |
$1K |
| 36416 |
|
381 |
315 |
$848.64 |
| 87591 |
Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe |
48 |
41 |
$844.48 |
| 87491 |
Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe |
49 |
41 |
$844.48 |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
93 |
70 |
$825.44 |
| 90460 |
Immunization administration through 18 years of age via any route, first or only component |
22 |
21 |
$460.44 |
| 99211 |
Office or other outpatient visit for the evaluation and management of an established patient, minimal severity |
41 |
28 |
$451.20 |
| S9083 |
Global fee urgent care centers |
35 |
25 |
$260.00 |
| 94760 |
|
177 |
163 |
$217.54 |
| 83986 |
|
62 |
55 |
$132.44 |
| 82947 |
|
50 |
42 |
$111.54 |
| 99000 |
|
17,574 |
15,385 |
$82.58 |
| 90686 |
|
35 |
33 |
$57.09 |
| 85014 |
|
30 |
20 |
$40.60 |
| J7620 |
Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme |
120 |
106 |
$28.97 |
| 81002 |
|
1,726 |
1,160 |
$23.93 |
| J7613 |
Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg |
15 |
14 |
$0.65 |
| G8427 |
Eligible clinician attests to documenting in the medical record they obtained, updated, or reviewed the patient's current medications |
98 |
76 |
$0.01 |
| 85018 |
|
199 |
157 |
$0.00 |
| A9150 |
Non-prescription drugs |
29 |
27 |
$0.00 |
| 99072 |
|
3,317 |
3,018 |
$0.00 |
| G2023 |
Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source |
427 |
395 |
$0.00 |
| A7003 |
Administration set, with small volume nonfiltered pneumatic nebulizer, disposable |
97 |
86 |
$0.00 |